tiprankstipranks
Advertisement
Advertisement

MPLT Stock Latest News

MapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position
Company AnnouncementsMapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position
2d ago
8K
MPLT
Canaccord starts MapLight with Buy into schizophrenia data
PremiumThe Fly
Canaccord starts MapLight with Buy into schizophrenia data
9d ago
MPLT
MapLight Therapeutics initiated with a Buy at Canaccord
PremiumThe Fly
MapLight Therapeutics initiated with a Buy at Canaccord
9d ago
MPLT
MapLight updates trial timelines and highlights CNS pipeline
PremiumCompany Announcements
MapLight updates trial timelines and highlights CNS pipeline
3M ago
8K
MPLT
MapLight Therapeutics expects topline results from ZEPHYR trial in Q3
PremiumThe Fly
MapLight Therapeutics expects topline results from ZEPHYR trial in Q3
3M ago
MPLT
MapLight Therapeutics receives fast track designation for ML-007C-MA for ADP
PremiumThe FlyMapLight Therapeutics receives fast track designation for ML-007C-MA for ADP
3M ago
MPLT
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors
Premium
Company Announcements
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors
3M ago
MPLT
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors
Premium
Company Announcements
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors
3M ago
MPLT
MapLight Therapeutics, SandboxAQ announce strategic collaboration
PremiumThe Fly
MapLight Therapeutics, SandboxAQ announce strategic collaboration
3M ago
MPLT
MapLight Therapeutics Advances CNS Drug Pipeline
PremiumCompany Announcements
MapLight Therapeutics Advances CNS Drug Pipeline
4M ago
MPLT
MapLight Therapeutics Completes IPO and Raises $296.5M
PremiumCompany Announcements
MapLight Therapeutics Completes IPO and Raises $296.5M
4M ago
8K
MPLT
MapLight Therapeutics reports Q3 EPS ($37.18) vs ($25.08) last year
PremiumThe Fly
MapLight Therapeutics reports Q3 EPS ($37.18) vs ($25.08) last year
4M ago
MPLT
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts
PremiumRatingsPositive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts
4M ago
MPLT
ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
Premium
The Fly
ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
4M ago
BMY
MPLT
MapLight Therapeutics initiated with an Outperform at Leerink
Premium
The Fly
MapLight Therapeutics initiated with an Outperform at Leerink
4M ago
MPLT
Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials
PremiumRatings
Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials
4M ago
MPLT
Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential
PremiumRatings
Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential
4M ago
MPLT
MapLight Therapeutics initiated with a Buy at Stifel
PremiumThe Fly
MapLight Therapeutics initiated with a Buy at Stifel
4M ago
MPLT
MapLight Therapeutics initiated with a Buy at Jefferies
PremiumThe Fly
MapLight Therapeutics initiated with a Buy at Jefferies
4M ago
MPLT
MapLight Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe FlyMapLight Therapeutics initiated with an Overweight at Morgan Stanley
4M ago
MPLT
Premium
Company Announcements
MapLight Therapeutics Closes Successful IPO and Private Placement
5M ago
8K
MPLT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >